Intensity Therapeutics, Inc. (INTS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.55
- As of
Kresmion compiles this page from INTS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
INTENSITY THERAPEUTICS, INC. (INTS): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
See the full INTS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INTS on one page. Preview it with sample data, then open it live with a free account.
Preview the INTS dossierActive signals for INTS
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 24.7%, EPS $-1.11 vs $-0.89 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 35.5% - EPS $-3.25 vs $-5.0363 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 32.8% - EPS $-1.5 vs $-2.2313 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 13.3% - EPS $-0.96 vs $-1.1067 estimate
FREE, NO ACCOUNT
Every signal on INTS, as it fires
New filings, 13F moves and cross asset signals on INTS land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, INTS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
INTS against its peers
INTS's return on equity of -97.7% ranks in the 56th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | INTS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.1M | n/a | 8 |
| Operating margin | n/a | -2454.5% | n/a | 7 |
| Net margin | n/a | -1788.3% | n/a | 8 |
| Return on equity | -97.7% | -152.8% | 56 | 16 |
| 1 year | -52.7% | -57.6% | 57 | 14 |
Peers (22): KPRX, GTBP, PHIO, BLRX, JAGX, VTGN, HEPA, SNTI, TOVX, GDTC, CALC, ADIL, CMMB, ASBP, BIVI, ZEOX, PLUR, MTVA, BCLI, ANEB, PASG, OTLC. Left out: CUBT (no annual filing), VICP (period gap), MBRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (INTS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INTS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INTS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.